Last Updated : June 30, 2017
Details
FilesGeneric Name:
Axitinib
Project Status:
Complete
Therapeutic Area:
Metastatic Renal Cell Carcinoma
Manufacturer:
Pfizer Canada Inc.
Brand Name:
Inlyta (RFA)
Project Line:
Reimbursement Review
Project Number:
PA0001-000
NOC Status at Filing:
Post NOC
Tumour Type:
Genitourinary
Indications:
Metastatic Renal Cell Carcinoma
Sponsor:
pCODR Provincial Advisory Group
Submission Date:
Stakeholder Input Deadline ‡:
pERC Meeting:
Notification to Implement Issued:
Recommendation Type:
N/A
Clarification:
Please note that the June pERC meeting was conducted over two days. The target for the posting of pERC Initial Recommendation remains as June 29, 2017.
Final Recommendation Issued (target date):
Request for Advice Question:
RFA Question from the Provincial Advisory Group
Is there evidence to fund axitinib as an alternative to everolimus for the second-line treatment of metastatic clear cell renal carcinoma?
pERC Meeting:
Note: The pCODR Provincial Advisory Group, PAG, has submitted a Request for Advice for the Final Recommendation for this drug and indication originally posted on March 7, 2013. The original axitinib (Inlyta) pCODR review can be found on the Inlyta for metastatic renal cell carcinoma (mRCC) details page: https://www.cadth.ca/inlyta-metastatic-renal-cell-carcinoma-mrcc-details.
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : June 30, 2017